DENVER, Sept. 22 /PRNewswire-FirstCall/ -- Myogen, Inc. (Nasdaq: MYOG), a
biopharmaceutical company focused on the discovery, development and
commercialization of small molecule therapeutics for the treatment of
cardiovascular disorders, today announced that J. William Freytag, President
and Chief Executive Officer, will present a corporate overview at the UBS
Global Life Sciences Conference.
The presentation will take place at 8:00 a.m. (Eastern) on Tuesday,
September 27, 2005. There will be a live webcast of the presentation, which
will be accessible through a link posted on our website, http://www.myogen.com, under
the investor relations section. The webcast will be available for replay on
Myogen's website through October 7, 2005.
Myogen has two product candidates in late-stage clinical development:
ambrisentan for the treatment of patients with pulmonary arterial hypertension
and darusentan for the treatment of patients with resistant systolic
hypertension. The Company, in collaboration with Novartis, also conducts a
target and drug discovery research program focused on the development of
disease-modifying drugs for the treatment of chronic heart failure and related
cardiovascular disorders. Please visit the company's website at
http://www.myogen.com.
Safe Harbor Statement
The anticipated presentation will contain forward-looking statements that
involve significant risks and uncertainties, including those to be discussed
in the presentation and others that can be found in the "Risk Factors" section
of Myogen's Form 10-K for the year ended December 31, 2004 and Myogen's
periodic reports on Form 10-Q and Form 8-K. Myogen does not undertake any
obligation to update any forward-looking statements contained in the
anticipated presentation as a result of new information, future events or
otherwise. The company cautions investors not to place undue reliance on the
forward-looking statements contained in this press release or the
presentation. No forward-looking statement can be guaranteed and actual
events and results may differ materially from those projected.
SOURCE Myogen, Inc.
 back to top
Related links:
http://www.myogen.com
CONTACT:
Derek K. Cole, Director, Investor Relations
of Myogen, Inc., +1-303-464-3986, derek.cole@myogen.com
|
